UK-based medical device manufacturer Rayner has acquired Swiss-based firm, This (Think in System) AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines.
The acquisition enhances Rayner’s breadth of high-quality products for cataract surgery, which includes intraocular lenses, ophthalmic viscosurgical devices, eye drops, pharmaceuticals, digital tools, and single-use recyclable instruments.
The acquisition enhances Rayner’s breadth of high-quality products for cataract surgery
Sophi (Swiss Ophthalmology Innovation) is an innovative phaco technology providing mobility, simplicity, and safety within the operating theatre. With triple pump fluidics, active IOP control, clean venturi and day cassette, cable free power supply and wireless communication, it has been described by Rayner as “a truly advanced surgical system” that “plays a central role in cataract surgery”.
“At Rayner we aspire to launch the highest quality products, inspired by surgeons and driven by science. Sophi shares this vision, and their machines are truly differentiated with breakthrough technology combined with stunning design which makes them such a good fit for Rayner,” said Tim Clover, Rayner CEO. “ I’m excited about their product range today, as well as what we will be planning together for tomorrow.”
Thomas Koeppel, Founder and CEO of Sophi, said “Sophi was created by viewing things from a completely new perspective; to redefine the requirements of a perfect phaco system by focusing on the point of view of the surgeon and their team. We saw the same philosophy in Rayner and are excited to combine in order to offer Sophi through an expanded commercial team and to accelerate our innovation projects.”
Medical professionals including Dr Erik L. Mertens, Founder and Medical Director of Medipolis Eye Centre, have commended Sophi for its ease of use.
“Sophi has been my primary phaco machine for the last three years and I would highly recommend it to fellow high-volume premium cataract and refractive surgeons. I have found its superior fluidics, ease of use and in-field support from the manufacturer to be highly differentiated,” he said in a statement issued by Rayner.
The acquisition closed on 17 January 2024.
